#1 Clinical Trials Search in Europe

Nirogacestat Hydrobromide

This article discusses the use of Nirogacestat Hydrobromide in clinical trials for patients with relapsed/refractory multiple myeloma (RRMM). Nirogacestat is being studied in combination with other anti-cancer treatments as part of the DREAMM5 platform study. This phase I/II trial aims to evaluate the safety, tolerability, and effectiveness of Nirogacestat when combined with drugs like Belantamab Mafodotin in patients who have received at least three prior lines of treatment.

Table of Contents

What is Nirogacestat?

Nirogacestat Hydrobromide, also known by its sponsor product code PF-03084014, is a promising new medication being studied for the treatment of multiple myeloma[1]. Multiple myeloma is a type of blood cancer that affects plasma cells, which are a crucial part of your immune system. This condition can lead to various complications, including bone problems, kidney issues, and a weakened immune system.

How it Works

Nirogacestat is classified as a gamma-secretase inhibitor[1]. Gamma-secretase is an enzyme that plays a role in cell signaling pathways, which are important for cancer cell growth and survival. By inhibiting this enzyme, Nirogacestat may help to slow down or stop the growth of cancer cells in multiple myeloma patients.

Clinical Trial Information

Nirogacestat is currently being studied in a clinical trial called DREAMM5[1]. This trial is specifically looking at how Nirogacestat works in combination with other anti-cancer treatments for patients with relapsed/refractory multiple myeloma (RRMM). Relapsed/refractory means that the cancer has either returned after treatment or has not responded well to previous treatments.

The trial is divided into two main phases:

  1. Dose Exploration Phase: This phase aims to determine the safety and best dosage of Nirogacestat when combined with other treatments.
  2. Cohort Expansion Phase: This phase will assess how well the treatment works at the determined dosage.

Potential Benefits

While the full benefits of Nirogacestat are still being studied, researchers hope that it may offer several advantages for multiple myeloma patients:

  • Improved response to treatment, especially for those who have not responded well to other therapies
  • Potential for longer-lasting remission
  • Possibility of combining with other treatments for enhanced effectiveness

Possible Side Effects

As with any medication, Nirogacestat may cause side effects. Some potential side effects being monitored in the clinical trial include[1]:

  • Gastrointestinal issues
  • Skin-related problems
  • Changes in blood electrolyte levels (such as phosphate, potassium, and magnesium)

It’s important to note that the full range of side effects is still being studied, and patients in the trial will be closely monitored for any adverse reactions.

Who Can Participate in the Trial?

The DREAMM5 trial has specific criteria for who can participate. Some key factors include[1]:

  • Patients must be 18 years or older
  • Have a confirmed diagnosis of multiple myeloma
  • Have received at least 3 prior lines of anti-myeloma treatments
  • Have measurable disease
  • Meet certain health criteria, including adequate organ function

There are also several factors that may exclude a person from participating, such as certain medical conditions or previous treatments. It’s important to discuss with your doctor whether you might be eligible for this or other clinical trials.

Conclusion

Nirogacestat Hydrobromide represents a promising new approach in the treatment of multiple myeloma, especially for patients who have not responded well to other therapies. While it’s still in the clinical trial phase, the research community is hopeful about its potential. As always, it’s crucial for patients to discuss all treatment options, including clinical trials, with their healthcare providers to determine the best course of action for their individual situation.

Aspect Details
Study Name DREAMM5
Study Type Phase I/II, Randomized, Open-label Platform Study
Main Drug Nirogacestat Hydrobromide (in combination with other treatments)
Condition Relapsed/Refractory Multiple Myeloma (RRMM)
Primary Objectives Safety, tolerability, and clinical activity assessment
Key Eligibility Adults with RRMM, ≥3 prior lines of treatment
Main Exclusions Prior gamma-secretase inhibitor use, certain electrolyte imbalances
Primary Endpoints Percentage of participants with dose-limiting toxicities, adverse events, and objective response rate

FAQ

  • What is Nirogacestat Hydrobromide? Nirogacestat Hydrobromide is an investigational drug being studied for the treatment of relapsed/refractory multiple myeloma. It is a gamma-secretase inhibitor that is taken orally in tablet form.
  • What is the DREAMM5 study? DREAMM5 is a phase I/II, randomized, open-label platform study that examines Belantamab Mafodotin alone and in combination with other anti-cancer treatments, including Nirogacestat, in patients with relapsed/refractory multiple myeloma.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults with confirmed multiple myeloma who have received at least 3 prior lines of treatment, including an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. They must also have measurable disease and adequate organ function.
  • What are the main objectives of the study? The main objectives are to determine the safety and tolerability of the drug combinations, establish recommended doses for phase 2, and assess the clinical activity of Nirogacestat in combination with other treatments compared to monotherapy in patients with RRMM.
  • Are there any specific exclusion criteria for the Nirogacestat sub-studies? Yes, some specific exclusions for Nirogacestat sub-studies include previous administration of a gamma-secretase inhibitor, conditions causing refractory electrolyte imbalances, and concomitant use of strong CYP3A4 inhibitors or inducers.

Ongoing Clinical Trials on Nirogacestat Hydrobromide

  • Study of Nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Italy The Netherlands Spain

  • Study of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Norway Poland Sweden

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • Relapsed/Refractory Multiple Myeloma (RRMM): Multiple myeloma that has returned after treatment (relapsed) or does not respond to treatment (refractory).
  • Nirogacestat Hydrobromide: An investigational drug being studied as a potential treatment for multiple myeloma. It is a gamma-secretase inhibitor taken orally in tablet form.
  • Belantamab Mafodotin: An antibody-drug conjugate targeting B-cell maturation antigen (BCMA), used in the treatment of multiple myeloma.
  • DREAMM5: A clinical trial platform studying Belantamab Mafodotin alone and in combination with other anti-cancer treatments for patients with relapsed/refractory multiple myeloma.
  • Phase I/II trial: A clinical trial that combines both phase I (focusing on safety and dosing) and phase II (assessing effectiveness) aspects of drug testing.
  • Gamma-secretase inhibitor: A type of drug that blocks the action of gamma-secretase, an enzyme involved in cell signaling pathways that may be important in cancer growth.
  • CYP3A4: An enzyme in the liver that helps metabolize many medications. Some drugs can inhibit or induce its activity, potentially affecting the metabolism of other drugs.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-of-belantamab-mafodotin-alone-and-with-drug-combination-for-patients-with-relapsed-refractory-multiple-myeloma/